2,084 Shares in Stryker Corporation $SYK Bought by L2 Asset Management LLC

L2 Asset Management LLC purchased a new stake in Stryker Corporation (NYSE:SYK) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,084 shares of the medical technology company’s stock, valued at approximately $656,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. VanderPol Investments L.L.C. raised its position in shares of Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after buying an additional 28 shares during the last quarter. KCM Investment Advisors LLC lifted its stake in shares of Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after buying an additional 28 shares during the period. Rossby Financial LCC grew its position in Stryker by 6.6% during the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after buying an additional 28 shares in the last quarter. Tcfg Wealth Management LLC increased its stake in Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after acquiring an additional 29 shares during the period. Finally, ICW Investment Advisors LLC increased its stake in Stryker by 0.6% during the fourth quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock valued at $1,791,000 after acquiring an additional 30 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Ronda E. Stryker sold 300,000 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 355,370 shares of company stock worth $119,447,201. Insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the subject of a number of research reports. JPMorgan Chase & Co. reduced their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Citigroup restated a “buy” rating on shares of Stryker in a research report on Thursday, August 13th. Wolfe Research lowered Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. BTIG Research reduced their target price on Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Finally, Raymond James Financial set a $370.00 price target on shares of Stryker in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Stock Up 1.0%

Shares of NYSE:SYK opened at $331.06 on Wednesday. The company’s fifty day moving average is $327.80 and its 200-day moving average is $331.95. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The company has a market capitalization of $126.98 billion, a PE ratio of 34.31, a P/E/G ratio of 2.09 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter last year, the company posted $3.13 EPS. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts predict that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.